Median Technologies: Launch of EUR22m capital increase to unlock EIB funds
Median Technologies has launched a EUR22m capital increase via a public offering of shares with warrants (ABSA), priced at EUR1.66 (at ~18% discount to 20-day VWAP), with 78% of the deal already secured via existing and new investors. The raise aimed to i) meet the drawing conditions of the TrancheMedian Technologies is engaged in medical imaging. Co. develops software applications for the interpretation and management of medical images, whose purpose is to automatically detect and quantitatively measure abnormalities that may be signs of diseases. In addition to being involved in patient care applications, Co.'s software is used today used by biotechnology companies and pharmaceutical companies during their oncology clinical trials. Co.'s activities are structured around three strategic areas: Imaging for patients with cancer; Imaging for oncology clinical trials and Imaging Phenomics.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.